A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-19 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Common adverse effects (2.4–42%) included agitation or irritability, tachycardia, hallucinations or delusions, confusion, pupil dilation, hypertension, drowsiness or lethargy, elevated creatine phosphokinase (CPK), nausea and vomiting, and others. Selected serious adverse effects included fever or hyperthermia in 3.8%, single seizure in 2.4%, coma in 1.4%, elevated creatinine in 1.4%, multiple seizures in 1.2%, rhabdomyolysis in 1.1%, respiratory depression in 0.9%, cardiac conduction disorder in 0.5%, and status epilepticus in 0.4%. There is a case report of severe neurological sequelae following a single typical recreational dose of LSD involving seizure and cardiorespiratory arrest. In general, psychedelics like LSD may rarely cause seizures in some individuals. The median lethal dose (LD50) of LSD in animals varies and is 50 to 60 mg/kg in mice, 16.5 mg/kg in rats, and 0.3 mg/kg in rabbits all given by injection. A well-known 1962 instance of an elephant named Tusko given 297 mg (~0.1 mg/kg) LSD by intramuscular injection proved fatal. These findings suggest that elephants may be much more sensitive to LSD in overdose than humans and other species. However, this instance has been mired in criticism and controversy due to miscalculation of LSD dose and concomitant post-LSD administration of promazine and pentobarbital. The experiment was repeated in two elephants with similar doses of LSD in 1984 without incident. Massive doses of LSD are largely managed by symptomatic treatments, and agitation can be addressed with benzodiazepines.
Cresskill is governed under the borough form of New Jersey municipal government, which is used in 218 municipalities (of the 564) statewide, making it the most common form of government in New Jersey. The governing body is comprised of the mayor and the borough council, with all positions elected at-large on a partisan basis as part of the November general election. A mayor is elected directly by the voters to a four-year term of office. The borough council includes six members elected to serve three-year terms on a staggered basis, with two seats coming up for election each year in a three-year cycle. The borough form of government used by Cresskill is a "weak mayor / strong council" government in which council members act as the legislative body with the mayor presiding at meetings and voting only in the event of a tie. The mayor can veto ordinances subject to an override by a two-thirds majority vote of the council. The mayor makes committee and liaison assignments for council members, and most appointments are made by the mayor with the advice and consent of the council. As of 2026, the mayor of the Borough of Cresskill is Republican John Morgan, who was appointed to serve a term of office ending on December 31, 2027. Members of the Cresskill Borough Council are Saverio Costa (R, 2028), Cheryl Furio (R, 2028), Arthur J. McLaughlin (D, 2026), Hector Olmo (R, 2026), Kathleen Savas (D, 2027), and Kathy M. Schultz-Rummel (R, 2027).
=== Earliest appearances of features === Hadrocodium, whose fossils date from approximately 195 million years ago, in the early Jurassic, provides the first clear evidence of a jaw joint formed solely by the squamosal and dentary bones; there is no space in the jaw for the articular, a bone involved in the jaws of all early synapsids.
Sources: en.wikipedia.org
There is no settled consensus in philosophy of mind on whether a machine can have a mind, consciousness or subjective experiences in the same sense that human beings do. This issue considers the internal experiences of the machine, rather than its external behaviour. Mainstream AI research considers this issue irrelevant because it does not affect the goals of the field: to build machines that can solve problems using intelligence. Russell and Norvig add that "[t]he additional project of making a machine conscious in exactly the way humans are is not one that we are equipped to take on." However, the question has become central to the philosophy of mind. It is also typically the central question at issue in artificial intelligence in fiction.
Ice-nine is a fictional material that appears in Kurt Vonnegut's 1963 novel Cat's Cradle. Ice-nine is described as a polymorph of ice which instead of melting at 0°C (32°F) melts at 45.8°C (114.4°F). When ice-nine comes into contact with liquid water below 45.8°C, it acts as a seed crystal and causes the solidification of the entire body of water, which quickly crystallizes as more ice-nine. As humans are 55-60% water, ice-nine kills nearly instantly when ingested or brought into contact with soft tissues exposed to the bloodstream, such as the eyes or lips. In the story, ice-nine is invented by Dr. Felix Hoenikker while working on the Manhattan Project in response to a suggestion from a Marine general, who complained about soldiers having to deal with mud on the battlefield. The project is abandoned when it becomes clear that any quantity of the substance would have the power to destroy all life on Earth. In the novel's climax, the Earth's oceans are accidentally frozen solid by ice-nine, prompting a doomsday scenario. Vonnegut encountered the idea of ice-nine while working at General Electric. He attributes the idea of ice-nine to his brother Bernard Vonnegut, who was researching the formation of ice crystals in the atmosphere. A later account of the events attributes the idea to the chemist Irving Langmuir, who devised the concept while helping H.G. Wells conceive ideas for stories. Vonnegut decided to adapt the idea into a story after Langmuir's death in 1957.
== Other products produced == The main products of malolactic fermentation are lactic acid, diacetyl, acetic acid, acetoin, and various esters. The amount and exact nature of these products depends on the species/strain of LAB conducting the malolactic fermentation and the condition influencing that wine (pH, available nutrients, oxygen levels, etc.). Some strains of O. oeni can synthesize higher alcohols which can contribute to fruity notes in the aroma of the wine. Additionally, some strains of the bacterium have beta-glucosidase enzymes that can break down monoglucosides which are aroma compounds attached to a sugar molecule. When the sugar component is cleaved, the rest of the compound becomes volatilized, meaning it can potentially be detected in the aroma bouquet of the wine. In the early 21st century, some strains of O. oeni were shown to use acetaldehyde by breaking it down into ethanol or acetic acid. While this may help for wines with excessive levels of acetaldehyde, for red wines, it can also destabilize the color of the wine by interfering with acetaldehyde's reaction with anthocyanins to create polymeric pigments that help create a wine's color.
Sources: en.wikipedia.org
== Chemical mechanism == The carbonyl group of the sugar reacts with the amino group of the amino acid, producing N-substituted glycosylamine and water The unstable glycosylamine undergoes Amadori rearrangement, forming ketosamines Several ways are known for the ketosamines to react further: Produce two water molecules and reductones Diacetyl, pyruvaldehyde, and other short-chain hydrolytic fission products can be formed. Produce brown nitrogenous polymers and melanoidins
== Principle == Capillary electrochromatography (CEC) combines the principles used in HPLC and CE. The mobile phase is driven across the chromatographic bed using electroosmosis instead of pressure (as in HPLC). Electroosmosis is the motion of liquid induced by an applied potential across a porous material, capillary tube, membrane or any other fluid conduit. Electroosmotic flow is caused by the Coulomb force induced by an electric field on net mobile electric charge in a solution. Under alkaline conditions, the surface silanol groups of the fused silica will become ionised leading to a negatively charged surface. This surface will have a layer of positively charged ions in close proximity which are relatively immobilised. This layer of ions is called the Stern layer. The thickness of the double layer is given by the formula:
== Gene == The PPY gene encodes an unusually short protein precursor of 95 amino acids in length. This precursor is cleaved to produce the signal peptide, the pancreatic polypeptide, the pancreatic icosapeptide, and a 5- to 7- amino-acid oligopeptide.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.